Asset management firm Viking Global Investors led a $120m Series B financing round for Affinivax, a clinical-stage biotechnology company. The round saw participation also from private equity firms Bain Capital Life Sciences and Ziff Capital Partners. “We are very pleased to welcome such a strong syndicate of new investors to Affinivax and look forward to benefiting from their deep experience. Having built the company to over 70 employees and advanced MAPS into clinical testing in less than 5 years, we are very excited to look ahead to our next phase of growth, taking our lead pneumococcal vaccine through Phase 3 testing and bringing several additional novel MAPS vaccines and immunotherapies into clinical trials," Steven B. Brugger, Affinivax CEO.